Amgen, a leading global biotechnology company, is excited to announce the establishment of a new Technology and Innovation Centre in Hyderabad, India. Set to be located in HITEC City, a prominent technology hub, the centre will occupy six floors of the RMZ Spire Tower. The facility is anticipated to become operational in the fourth quarter of 2024, with the capacity to house up to 3,000 professionals.

The new site in Hyderabad marks a significant milestone in Amgen’s strategic expansion, aimed at building and scaling cutting-edge technology solutions and digital capabilities. The centre will play a crucial role in enhancing efficiencies across the company’s global operations.

Amgen’s Hyderabad site will offer a wide range of roles across key areas, including artificial intelligence (AI), data science, life sciences, and additional global capabilities, which will be developed over time. The establishment of this centre highlights Amgen’s commitment to leveraging India’s rich talent pool, particularly in technology and life sciences, to drive innovation and serve patients worldwide.

Leading Amgen’s expanded operations in India is Som Chattopadhyay, appointed as the national executive. With a revenue of $28.2 billion in 2023, Amgen continues to be a pioneering force in the biotechnology sector, with nearly 27,000 employees across approximately 100 countries, including India.

Commenting on the new venture, David M. Reese, Executive Vice President and Chief Technology Officer at Amgen, stated, “At a time when the world is facing the challenges of an aging population, the integration of biotechnology and technology allows us to innovate with unprecedented speed, confidence, and efficiency. Establishing this new centre in India, a country renowned for its exceptional technology and life sciences talent, is a key step forward in our mission to deliver innovative solutions for patients.”

Chief Minister Anumula Revanth Reddy welcomed Amgen’s investment, noting, “Hyderabad’s position as a hub for innovation and technology is further solidified with Amgen’s new centre. We are delighted to support Amgen’s commitment to advancing healthcare through technological innovation.”

Also Read: Fortis Healthcare to Acquire 31% Stake in Agilus Diagnostics for INR 1,780 Crore, Bolstering Its Position in Diagnostics

Amgen joins a growing number of multinational pharmaceutical and medtech companies that are establishing Global Capability Centres (GCCs) in India, particularly in the technology sector. These centres are critical in supporting global operations and developing AI-driven solutions for optimizing manufacturing, identifying drug discovery targets, and simulating clinical trials, among other innovations.

Recent investments by major players such as Sanofi, AstraZeneca, and Novartis underscore the growing importance of India as a key player in the global biotechnology and pharmaceutical sectors. Amgen’s new Technology and Innovation Centre is a testament to this trend, positioning the company to continue its leadership in biotechnology on a global scale.

Like 1

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.